Population‐based study of surgical treatment with and without tumour resection in patients with locally recurrent rectal cancer. BJS 2019; 106: 790-798.
Published: 18th February 2019
Authors: K. Westberg, G. Palmer, F. Hjern, T. Holm, A. Martling
Population‐based studies of treatment of locally recurrent rectal cancer (LRRC) are lacking. The aim was to investigate the surgical treatment of patients with LRRC at a national population‐based level.
All patients undergoing abdominal resection for primary rectal cancer between 1995 and 2002 in Sweden with LRRC as a first event were included. Detailed information about treatment, complications and outcomes was collected from the medical records. The patients were analysed in three groups: patients who had resection of the LRRC, those treated without tumour resection and patients who received best supportive care only.
In all, 426 patients were included in the study. Of these, 149 (35·0 per cent) underwent tumour resection, 193 (45·3 per cent) had treatment without tumour resection and 84 (19·7 per cent) received best supportive care. Abdominoperineal resection was the most frequent surgical procedure, performed in 65 patients (43·6 per cent of those who had tumour resection). Thirteen patients had total pelvic exenteration. In total, 63·8 per cent of those whose tumour was resected had potentially curative surgery. After tumour resection, 62 patients (41·6 per cent) had a complication within 30 days. Patients who received surgical treatment without tumour resection had a lower complication rate but a significantly higher 30‐day mortality rate than those who underwent tumour resection (10 versus 1·3 per cent respectively; P = 0·002). Of all patients included in the study, 22·3 per cent had potentially curative treatment and the 3‐year survival rate for these patients was 56 per cent.
LRRC is a serious condition with overall poor outcome. Patients undergoing curative surgery have an acceptable survival rate but substantial morbidity. There is room for improvement in the management of patients with LRRC.Full text
You may also be interested in
Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Authors: T. Akiyoshi, N. Tanaka, K. Kiyotani, O. Gotoh, N. Yamamoto, K. Oba et al.
BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Authors: J.‐B. Bachet, N. Moreno‐Lopez, L. Vigano, U. Marchese, M. Gelli, L. Raoux et al.
Propensity score‐matched analysis of oncological outcome between stent as bridge to surgery and emergency resection in patients with malignant left‐sided colonic obstruction.
Authors: F. J. Amelung, W. A. A. Borstlap, E. C. J. Consten, J. V. Veld, E. E. van Halsema, W. A. Bemelman et al.
Authors: A. Zaborowski, A. Stakelum, D. C. Winter
Authors: Z. Lakkis, D. Vernerey, D. Mege, J.‐L. Faucheron, Y. Panis, J.‐J. Tuech et al.
Association between surgeon special interest and mortality after emergency laparotomy. BJS 2019; 106: 940-948.
Authors: H. Boyd‐Carson, B. Doleman, P. J. J. Herrod, I. D. Anderson, J. P. Williams, J. N. Lund et al.
Incidence and lifetime risk of hospitalization and surgery for diverticular disease. BJS 2019; 106: 930-939.
Authors: F. Sköldberg, J. Granlund, A. Discacciati, F. Hjern, P. T. Schmidt, O. Olén et al.
Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life. BJS 2019; 106: 805-805.
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. BJS 2019; 106: 728-728.
Authors: B. Shinkins, J. N. Primrose, S. A. Pugh, B. D. Nicholson, R. Perera, T. James et al.
Authors: I. S. Reynolds, S. J. Furney, E. W. Kay, D. A. McNamara, J. H. M. Prehn, J. P. Burke et al.
Randomized clinical trial
Randomized clinical trial of liposomal bupivacaine transverse abdominis plane block versus intrathecal analgesia in colorectal surgery. BJS 2019; 106: 692-699.
Authors: D. T. Colibaseanu, O. Osagiede, A. Merchea, C. T. Ball, E. Bojaxhi, J. K. Panchamia et al.
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer. BJS 2019; 106: 922-929.
Authors: B. J. Quiram, J. Crippa, F. Grass, J. K. Lovely, K. T. Behm, D. T. Colibaseanu et al.